Indications of capmatinib

Capmatinib (Capmatinib) is a targeted therapy drug for non-small cell lung cancer (NSCLC). It is mainly suitable for patients with a specific type of lung cancer, namely conditions caused by abnormal expression of MET (tyrosine kinase) or gene mutations. Its indications mainly include the following aspects:

1.METoverexpressed non-small cell lung cancer: Capmatinib is designed to treat patients with METoverexpressed non-small cell lung cancer. MET is a key cell growth signaling pathway. When this pathway is abnormally expressed or activated, it may lead to abnormal growth and spread of cancer cells. Therefore, the mechanism of action of capmatinib is to inhibit the activity of MET kinase and block this abnormal signaling pathway, thereby inhibiting the progression of lung cancer.

2. Non-small cell lung cancer with MET gene mutations: Capmatinib is also considered an effective treatment option for patients with NSCLC with MET gene mutations. This gene mutation may lead to overactivation of the MET pathway and promote the occurrence and development of lung cancer. The targeting effect of capmatinib helps interfere with this abnormal signaling and inhibits tumor growth.

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive. Generic drugs on the market abroad are much cheaper, mainly Laos generic drugs, the price is around 3,000 to 4,000 yuan, and the ingredients of original drugs and generic drugs are basically the same.